Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYLANID vs SENSIPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.
Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.
Heart failure,Atrial fibrillation,Atrial flutter
Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Hypercalcemia in patients with parathyroid carcinoma,Severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy
0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.
30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.
Terminal half-life 33–36 hours (anuric patients up to 110 hours); requires dose adjustment in renal impairment.
The terminal elimination half-life of cinacalcet is approximately 30 to 40 hours in patients with normal renal function, supporting once-daily dosing. Steady-state concentrations are achieved within 7 days.
Hepatic metabolism via hydrolysis and conjugation; not significantly metabolized by CYP enzymes.
Hepatic via CYP3A4, CYP2D6, CYP1A2; major metabolites are inactive.
Renal (≈70% as unchanged drug), biliary/fecal (≈30%)
Renal excretion of unchanged drug and metabolites accounts for approximately 84% of the administered dose; fecal excretion accounts for approximately 11%. The primary metabolic pathway is CYP3A4-mediated oxidation, followed by glucuronidation.
25–30% bound to albumin.
Cinacalcet is approximately 93 to 97% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
7.5–10 L/kg; wide distribution indicating extensive tissue binding.
The volume of distribution is approximately 1000 L (about 14 L/kg in a 70 kg individual), indicating extensive tissue distribution.
Oral: 70–85% (variable, dependent on gastrointestinal absorption).
Oral bioavailability is approximately 20 to 25% due to first-pass metabolism; administration with food increases bioavailability by approximately 50% compared to fasting.
GFR <30 m L/min: reduce dose by 50% and extend dosing interval to every 12-24 hours. GFR 30-50 m L/min: consider 25% dose reduction. Monitor digoxin levels.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >= 30 m L/min). Not recommended for patients with severe renal impairment (Cr Cl < 30 m L/min) due to lack of data.
Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use with caution, reduce dose by 50% and monitor levels. Not recommended in severe hepatic impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Use with caution in severe hepatic impairment (Child-Pugh Class C) with no specific dose recommendations.
Loading dose: 10-15 mcg/kg IV over 5 minutes. Maintenance: 5-10 mcg/kg orally every 8-12 hours. Maximum daily dose: 250 mcg in children <2 years, 500 mcg in older children.
Safety and effectiveness in pediatric patients have not been established.
Initiate with 50% of usual adult dose due to reduced renal function and increased sensitivity. Maximum loading dose: 0.2 mg IV. Maintenance: 0.1 mg every 12 hours. Monitor electrolytes and ECG.
No specific dose adjustment; dosing should be based on renal function. Elderly patients may have decreased renal function; monitor serum calcium and i PTH levels closely.
None.
None.
Risk of digitalis toxicity; monitor renal function and electrolytes; caution in hypokalemia, hypomagnesemia, and hypercalcemia.
Hypocalcemia: monitor serum calcium, especially during initiation and dose titration,Seizures: risk due to hypocalcemia,QT prolongation: caution in patients with history of QT interval prolongation or on concurrent QT-prolonging drugs,Hypotension: possible during dialysis use,Adynamic bone disease: potential with oversuppression of PTH
Ventricular fibrillation,Hypersensitivity to cardiac glycosides,Digitalis toxicity
Hypocalcemia (serum calcium < 8.4 mg/d L)
Avoid high-potassium foods (bananas, oranges, spinach) unless directed; hypokalemia increases toxicity. Take with food to reduce GI upset. Do not take with high-fiber meals as may reduce absorption.
SENSIPAR should be taken with food or shortly after a meal to enhance absorption. No specific foods are contraindicated, but avoid high-calcium meals immediately before or after dosing as they may reduce absorption. Grapefruit and grapefruit juice may increase cinacalcet levels; avoid concurrent use.
Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Second and third trimesters: Maternal toxicity (arrhythmias, electrolyte disturbances) may cause fetal hypoxia or growth restriction. Avoid toxicity. Category C.
First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; potential fetal/neonatal hypocalcemia due to maternal calcium-sensing receptor modulation. Risk cannot be excluded.
Acylanid is excreted into breast milk in low amounts (M/P ratio not established; estimated <1% of maternal dose). No adverse effects reported in nursing infants. Use with caution, monitor infant for bradycardia or arrhythmias.
No human data on excretion in breast milk; M/P ratio unknown. Potential for serious adverse reactions (e.g., hypocalcemia) in nursing infants; decision to discontinue breastfeeding or drug based on importance of drug to mother.
Increased volume of distribution and renal clearance in pregnancy may reduce serum levels; monitor drug levels and adjust dose to maintain therapeutic range (0.5-2 ng/m L). Start at lower doses if hypokalemia or preeclampsia present.
No specific dose adjustment guidelines; pharmacokinetics in pregnancy unknown. Monitor serum calcium frequently and adjust dose to maintain target calcium levels. Consider that volume of distribution and clearance may increase, potentially requiring higher doses.
Acylanid (lanatoside C) is a digitalis glycoside with rapid onset (IV 10-30 min) and moderate duration; use in atrial fibrillation with rapid ventricular response, especially in acute settings. Monitor renal function due to renal elimination; toxicity risk increases with hypokalemia, hypomagnesemia, hypercalcemia. Adjust dose in renal impairment (Cr Cl <50 m L/min). Therapeutic drug monitoring: target serum level 0.5-2 ng/m L (drawn >6-8 hours post-dose).
SENSIPAR (cinacalcet) is a calcimimetic used for secondary hyperparathyroidism in CKD on dialysis and for hypercalcemia in parathyroid carcinoma. Monitor serum calcium closely; hypocalcemia is a common adverse effect. Do not initiate if serum calcium is below the lower limit of normal. Administer with food or shortly after a meal to increase absorption. Dose adjustments may be needed with moderate to severe hepatic impairment.
Take exactly as prescribed; do not skip doses or double up. Missed dose: take if within 12 hours, otherwise skip.,Monitor for signs of toxicity: nausea, vomiting, diarrhea, visual disturbances (yellow-green halos, blurred vision), confusion, irregular heartbeat.,Avoid OTC medications without consulting prescriber, especially antacids, laxatives, and antiarrhythmics.,Keep regular appointments for blood tests (digoxin level, kidney function, electrolytes).,Report weight gain >2 lbs/day, swelling, shortness of breath, or palpitations.
Take this medication with food or right after a meal.,Do not split, crush, or chew tablets; swallow whole.,Report symptoms of low calcium: muscle cramps, numbness, tingling, or seizures.,Keep all lab appointments for calcium and PTH monitoring.,Avoid taking with other medications without consulting your doctor; some may interact.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYLANID vs SENSIPAR, answered by our medical review team.
ACYLANID is a Cardiac Glycoside that works by Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.. SENSIPAR is a Calcimimetic that works by Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYLANID and SENSIPAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYLANID is: 0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.. The standard adult dose of SENSIPAR is: 30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYLANID and SENSIPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYLANID is classified as Category C. Acylanid is a cardiac glycoside with limited data in pregnancy. First trimester: No specific malformations reported, but potential for fetal cardiac effects due to mechanism. Secon. SENSIPAR is classified as Category C. First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.